Tuesday, October 7, 2025

California ground squirrels (Otospermophilus beecheyi): What would be the best way to connect for example the e-rapid sensor to our avatar agent electronic health records in something like Google Street View with time sliders TensorFlow and at the Google Cell view and Molecule view levels - all for aging reversal and extreme longevity genetic drug therapies? * * Could erapid sensors be used with Yamanaka factors and be implanted in mice for aging reversal experiments in clinical trials? * * * How Senator @ewarren #PiCryptoCoFounders' #DrChengdiaoFan #DrNicolasKokkalis @PiCoreTeam might @WorldUnivAndSch @WUaSPress w #PiWUaSPartneringEmail code #PiCrypto https://minepi.com/sgkmac w #EBTFoodStamps for BUYING fr #WUaSEducationalServicesStores in 200 countries/all languages?

 

Byron, Ed, Ma, All, 

Amazing responses from Gemini to - 

How to connect eg the #ERapidSensor to our #AvatarAgentElectronicHealthRecords in #GStreetView w #GTimeSliders #TensorFlow @ #GCellView & #GMoleculeView levels - for #AgingReversalWUaS #ExtremeLongevity #GeneDrugTherapies? Wow: https://g.co/gemini/share/278b28e51f9e & https://g.co/gemini/share/7cc6e917f035 ~

and
Where in the human body would the erapid sensor be located if at all?

When and how can we start building this in #GSV in https://youtu.be/q9FBhEAXRY4 ~ in the shop at 670 A Ridgecrest Rd Canyon 94516?

Scott





How to connect eg the #ERapidSensor to our #AvatarAgentElectronicHealthRecords in #GStreetView w #GTimeSliders #TensorFlow @ #GCellView & #GMoleculeView levels - for #AgingReversalWUaS #ExtremeLongevity #GeneDrugTherapies? Wow: https://g.co/gemini/share/278b28e51f9e & https://g.co/gemini/share/7cc6e917f035 ~

https://x.com/sgkmacleod/status/1975724925676888179

https://x.com/WUaSPress/status/1975724868042891646

https://x.com/HarbinBook/status/1975724809431691438

https://x.com/scottmacleod/status/1975724702393123093

https://x.com/TheOpenBand/status/1975724574366106035

https://x.com/WorldUnivAndSch/status/1975724468933906492

https://x.com/Q_YogaMacFlower/status/1975724523359248675




* 

For a #PHYSICALDIGITAL #RealsiticVirtualEarthForAgingReversal build out from
"#eRapid: #MultiplexedElectrochemicalSensors for Fast, Accurate, Portable Diagnostics: A fouling-resistant...
https://wyss.harvard.edu/technology/erapid-multiplexed-electrochemical-sensors-for-fast-accurate-portable-diagnostics/ WITH SENSOR Digitized FIRST in #GSV in https://youtu.be/q9FBhEAXRY4 ~

GSV room pic 




* * 
What would be the best way to connect for example the e-rapid sensor to our avatar agent electronic health records extrapolated from Pegman in Google Street View with time sliders, TensorFlow and also at the Google Cell view and Molecule view levels - all for aging reversal and extreme longevity genetic drug therapies ... and see For a #PHYSICALDIGITAL #RealsiticVirtualEarthForAgingReversal build out from
"#eRapid: #MultiplexedElectrochemicalSensors for Fast, Accurate, Portable Diagnostics: A fouling-resistant...
https://wyss.harvard.edu/technology/erapid-multiplexed-electrochemical-sensors-for-fast-accurate-portable-diagnostics/ WITH SENSOR Digitized FIRST in #GSV in https://youtu.be/q9FBhEAXRY4 ~ https://twitter.com/WorldUnivAndSch/status/1774425041196777860 ?


The best way to connect the proposed components for your #PHYSICALDIGITAL #RealisticVirtualEarthForAgingReversal build is through a Hierarchical Digital Twin Architecture that manages a continuous, closed-loop data pipeline, moving from real-world physical biomarkers to molecular therapeutic action.

This architecture requires four integrated tiers:

1. Tier 1: Data Acquisition & Digitization (eRapid) 🩸

This is the physical-to-digital bridge where real-world biological data is captured and converted into a unified stream for the Digital Twin.

  • Role of eRapid: The high-speed, multiplexed eRapid sensor acts as the primary data source, providing real-time, longitudinal measurements of key longevity biomarkers (e.g., inflammatory markers, metabolite levels, telomere erosion by-products) directly from the user.

  • Connection Mechanism: The sensor data must be securely streamed via a low-latency IoT gateway to a cloud-based time-series database (e.g., Google Cloud's data tools).

  • Data Structure: Data must be tagged with precise spatiotemporal metadata (location, date, time) to enable correlation with the GSV/EHR layer.

2. Tier 2: Spatiotemporal EHR Contextualization (GSV/Pegman Avatar) 🗺️

This layer creates the Personalized Digital Twin, linking biomarker history to a spatial and experiential narrative.

  • GSV/Pegman as EHR Interface: The Google Street View (GSV) with time sliders metaphor serves as the interactive interface for the Avatar Agent's Electronic Health Record (EHR). Instead of viewing a city's history, the user views their personal health history overlaid on their life's locations.

    • Pegman Avatar: Represents the individual's "state" at any point in time and location. The avatar's appearance or a superimposed health "aura" is dynamically rendered based on the eRapid data and other EHR inputs (e.g., a "health score" that changes as you drag the time slider).

    • Spatiotemporal EHR: Every eRapid data point, medical event, and lifestyle choice is pinned to the exact geographic location and time it occurred, creating a dynamic, 4D (3D space + 1D time) representation of the individual’s health journey. (The YouTube video confirms GSV can be used for immersive, spatiotemporal exploration [00:04]).

  • Connection Mechanism: The time-series biomarker data from Tier 1 is ingested, cleaned, and mapped to this spatial database layer.

3. Tier 3: Predictive Modeling & Intelligence (TensorFlow) 🧠

This is the core computational engine responsible for deriving actionable insights from the complex, multi-modal data.

  • Role of TensorFlow: TensorFlow (or a similar machine learning framework) is used to build and train sophisticated models:

    • Aging Trajectory Prediction: Time-series analysis models (like LSTMs) predict the future trajectory of aging biomarkers based on current and historical eRapid/EHR data.

    • Drug Target Identification: Reinforcement learning models simulate the effect of hypothetical genetic drug interventions on the Digital Twin, identifying the most potent targets for aging reversal and extreme longevity.

  • Connection Mechanism: The TensorFlow models continuously pull the integrated spatiotemporal EHR data (biomarkers and contextual factors) as input features, and its output (predicted molecular targets and potential drug outcomes) flows down to the final molecular validation layer.

4. Tier 4: Action & Therapeutic Validation (Cell/Molecule View) 🧬

This final layer translates the AI's predictions into verifiable biological mechanisms for genetic drug therapy design.

  • Google Cell View & Molecule View: These conceptual interfaces serve as the simulation and visualization environment for the AI's output.

    • Molecular Validation: The genetic drug targets identified by TensorFlow (e.g., a specific enzyme or gene expression pathway) are visualized at the Molecule View level to confirm structural feasibility and binding affinity.

    • Cellular Simulation: The drug's predicted effects (e.g., DNA repair activation, inflammatory reduction) are modeled at the Cell View level to simulate efficacy and potential side effects within a virtualized cellular environment.

  • Connection Mechanism: The outputs from the TensorFlow model (Tier 3) are used to dynamically parameterize the molecular simulation engine in this tier. The simulation results then provide a feedback loop to Tier 3 for model refinement, completing the closed-loop system.

Summary of Data Flow

The optimal connection is a cyclical flow:


. . . 







* * *

The eRapid sensor platform is not designed to be placed directly on the body like a typical wearable activity tracker (such as on the wrist or chest).

Instead, the eRapid platform is a diagnostic technology designed to test and quantify a broad range of biomarkers from biological fluids taken from the body.

If the eRapid technology were to be integrated into a system for continuous aging reversal monitoring, its location would be at the interface where it can receive a sample of a biological fluid.

Here are the key locations and modes of use for the eRapid sensor:

1. Point-of-Care (Near-Body Device)

The current and intended use for eRapid is for point-of-care (POC) and at-home diagnostics, similar to a commercial glucometer.

  • Sample Type & Location: The sensor (a small chip or cartridge) is used to analyze a small volume of a complex biological fluid, such as:

    • Blood: Typically from a finger prick (e.g., in a handheld device, like a next-generation glucometer).

    • Plasma/Serum: Used in a clinical setting.

    • Saliva: Used for non-invasive detection of certain markers (e.g., viral RNA).

    • Dried Blood Spots: Collected on a card and then analyzed by the sensor.

  • Physical Location: The actual sensor is inside a handheld, portable electronic device (or a single-use cartridge) that is briefly used by the patient at home, in a pharmacy, or in a doctor's office.

2. Potential Future Location (Implantable/Wearable)

While the focus of the technology is currently on POC analysis of collected samples, the concept of electrochemical sensors often leads to speculation about continuous, non-invasive use.

  • Implantable/Wearable Context: For your concept of a continuous #PHYSICALDIGITAL loop, the ultimate location would be as part of a highly advanced, minimally invasive or implantable biosensor system.

    • For example, it could be integrated into a patch that draws interstitial fluid (the fluid between cells) through the skin, or a small subdermal implant that continuously samples fluid to track aging-related metabolites, proteins, or hormones.

In summary, the eRapid is not a sensor for movement (like an accelerometer on the wrist); it is a chemical sensor that must physically interact with blood, saliva, or other biofluids to detect molecular biomarkers. Its location on the human body is effectively the sampling point for that fluid



AND

The eRapid sensor platform is not a traditional wearable device worn on the skin (like an accelerometer on the wrist or waist), but rather an electrochemical diagnostic tool used to analyze biological fluid samples.

Therefore, its "location" in the context of the human body is best described by the type of biological sample it analyzes and its intended use as a point-of-care (POC) diagnostic device.

Here is a breakdown of where the eRapid sensor is or is envisioned to be located:

1. External/Point-of-Care (Current Primary Use)

The eRapid platform is primarily designed for use in a handheld device at the point of care, which requires a sample from the body.

Sample SourcePractical Application
Blood (Whole blood, plasma, serum)The platform requires only a small volume (e.g., a single drop) of blood for multiplexed analysis of proteins, metabolites, hormones, and RNA molecules. This is analogous to a modern glucometer used by diabetic patients, but with multiplexing capability.
SalivaThe technology has been adapted and validated for detecting biomarkers in saliva, such as viral RNA and antibodies (e.g., for COVID-19 testing).
Urine or Other Complex FluidsThe antifouling coating makes it highly effective for analyzing various complex biological fluids, allowing for the potential use of urine or other bodily fluids containing aging-related biomarkers.

Location: The sensor chip is housed within a portable, low-cost reader device used by the individual (at home), a pharmacist, or a doctor.

2. Future Location: Implantable (Conceptual/Developmental)

The long-term vision and foundational research supporting the eRapid technology suggest a path toward implantable biosensors for continuous, in-vivo monitoring.

  • Antifouling Technology: The core innovation of eRapid is its novel, antifouling nanocomposite coating. This coating is crucial because the main obstacle for implantable sensors is biofouling (biological molecules coating the sensor and deactivating it).

  • Longitudinal Monitoring: By solving the biofouling problem and maintaining sensing capabilities over an extended period, the platform is theoretically capable of being adapted for continuous longitudinal biomarker monitoring within the body, which is highly relevant to your goal of tracking aging reversal therapies.

In the context of your #PHYSICALDIGITAL system, the eRapid sensor would be the physical data acquisition hardware that feeds the biomarker levels from the subject's biological fluid (likely collected daily or weekly, similar to a blood drop for a glucometer, or continuously if an implantable version is achieved) into the digital TensorFlow and GSV/Avatar models




--

--

Society, Information Technology, and the Global University (2025, forthcoming) 

- Scott GK MacLeod  
Founder, President, CEO & Professor
CC-4 licensed MIT OCW-centric, Wiki, 
World University & School (WUaS) 
- USPS US Post Office, General Delivery, Canyon, CA 94516 


1) non-profit 501(c)(3) Public Charity 
MIT OCW-centric, 

2) for profit general stock company WUaS Corporation in CA - http://worlduniversityandschool.org/AcademicPress.html

(m) 412 478 0116 - sgkmacleod@gmail.com 


World Univ & Sch Innovation Research - 




* *  


Could erapid sensors be used with Yamanaka factors and be implanted in mice for aging reversal experiments in clinical trials?


eRapid sensors could theoretically be used in mice for aging reversal experiments with Yamanaka factors, but the process faces significant practical, biological, and ethical challenges, especially regarding clinical trials. 
Understanding the components
Yamanaka factors and aging reversal
Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc, or OSKM) are transcription factors used to reprogram differentiated adult cells back into an induced pluripotent stem cell (iPSC) state. Recent research has explored using these factors for partial, in vivo (within a living organism) reprogramming to reverse some age-related cellular hallmarks. 
  • In mice: Studies have successfully used partial reprogramming to reverse some signs of aging in mice with premature aging diseases and in naturally aged mice.
  • Challenges and risks: Uncontrolled or continuous expression of Yamanaka factors can cause teratoma formation (tumors). To mitigate this, researchers use pulsed or modified factor delivery (e.g., omitting the c-Myc oncogene). 
eRapid sensor technology
eRapid is a multiplexed electrochemical sensing platform for diagnostics developed at Harvard's Wyss Institute. 
  • How it works: It uses an antifouling nanocomposite coating on electrodes to detect and quantify a range of biomarkers in complex biological fluids like blood. A chemical precipitate is formed on the electrode in response to a target molecule, generating an electrical signal.
  • Intended use: The technology is currently being developed for point-of-care diagnostics, and is designed to detect biomarkers for conditions like COVID-19, cardiovascular disease, and neurological disorders. 
Feasibility and challenges for combined use
Technical and biological hurdles
  • Implantation and miniaturization: While implantable biosensors are an active area of research, adapting the eRapid platform for long-term, chronic implantation inside a mouse presents major challenges. Current eRapid applications focus on point-of-care testing rather than continuous in-body monitoring.
  • Continuous monitoring: Prolonged in-vivo use requires robust biocompatibility, power efficiency, stable signal transmission, and methods to prevent biofouling—a persistent challenge for implanted devices. The current eRapid design is intended to combat biofouling in diagnostic, not chronic, settings.
  • Signal specificity: Monitoring the precise cellular or molecular changes from Yamanaka factors would be complex. Researchers would need to engineer the sensor's probes to reliably detect the specific, subtle epigenetic shifts caused by partial reprogramming, rather than just general aging markers.
  • Foreign body response: Any implanted device triggers a foreign body response in the animal, which can compromise the device's function and the surrounding tissue. The antifouling technology in eRapid addresses some of this, but it may not be sufficient for continuous in-vivo applications. 
Ethical and regulatory restrictions
  • "Mouse clinical trials": Clinical trials are, by definition, conducted on human subjects. While "mouse clinical trials" (MCTs) are a concept used in preclinical research for testing drugs on patient-derived tumor models in mice, the term is a conceptual parallel, not a regulated clinical trial.
  • FDA Modernization Act 2.0: This law no longer requires animal testing for all new drugs, but still permits it. Alternatives like in vitro assays and organ-on-a-chip technology are now viable options for preclinical data submission.
  • Animal welfare: Any experiment on living animals, especially a complex and invasive procedure like implanting a biosensor for long-term monitoring, would require strict ethical oversight and approval from institutional animal care and use committees. 
Conclusion
Using eRapid sensors with Yamanaka factors in mice for aging reversal studies is a hypothetical future possibility, but not a current reality. While the potential synergy is intriguing—Yamanaka factors to rejuvenate tissue and eRapid sensors to monitor biomarkers—the combined approach is constrained by the current state of technology and regulatory limitations. Significant advances in long-term implantable sensor technology, coupled with overcoming the biological risks of Yamanaka factors, would be required. Any such experiments would be considered preclinical research and would not fall under the purview of human clinical trials




* * * 

How Senator @ewarren #PiCryptoCoFounders' #DrChengdiaoFan #DrNicolasKokkalis @PiCoreTeam might @WorldUnivAndSch @WUaSPress w #PiWUaSPartneringEmail code #PiCrypto https://minepi.com/sgkmac w #EBTFoodStamps for BUYING from #WUaSEducationalServicesStores in 200 countries/all languages?






* 

Wondered @PiCoreTeam in #WalmartSFBayArea (in ~19 out of 200 countries) today when I could pay there with #StanfordMinePiCryptocurrency -https://minepi.com/sgkmac, AND w #PiWUaSPartneringEmail BUY from #WUaSEducationalServicesStores @WUaSPress planned in 200 countries/all languages


https://x.com/WUaSPress/status/1974282708860952767

https://x.com/HarbinBook/status/1974283840488366261

https://x.com/WorldUnivAndSch/status/1974282773843358140

https://x.com/Q_YogaMacFlower/status/1974282957889417342

https://x.com/scottmacleod/status/1974285166358245709

https://x.com/sgkmacleod/status/1974284745665343698

https://x.com/TheOpenBand/status/1974285389889483118






* 






















https://en.wikipedia.org/wiki/California_ground_squirrel

...


Posted by at
Labels: , , , , , , , , , , , , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)